“We confirmed on Wednesday that the first of Baxter's BAX two phase III IVIG for Alzheimer's trials has now completed enrollment,” JP Morgan wrote in a report this morning.
“An additional 30 patients were enrolled in the trial versus plan bringing total enrollment to 390 patients randomized to either (a) 400mg of IVIG/kg of bodyweight every 2 weeks; (b) 200mg of IVIG/kg; or (c) a placebo solution. Patients will be dosed and followed for 18 months with the last patient now expected to reach follow-up in January 2013. Given time for data gathering and analysis, we should see headline data by mid-2013.”
Baxter closed Wednesday at $60.58.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in